Antibiotic Usage (AU) Report
Days of Therapy by Location and Antimicrobial
336
Total DOT
1409
Patient Days
238.47
DOT/1000 PD
6
Locations
Usage by Antimicrobial Category
| Category | Location | Month | Total DOT |
|---|---|---|---|
| Cephalosporins 3rd Gen | A6N | 2025-12 | 3 |
| Cephalosporins 4th Gen | A6N | 2025-12 | 5 |
| Glycopeptides | A6N | 2025-12 | 3 |
| Nitroimidazoles | A6N | 2025-12 | 4 |
| Antifungals - Azoles | A6N | 2026-01 | 4 |
| Aminoglycosides | G5S | 2025-12 | 3 |
| Antifungals - Azoles | G5S | 2025-12 | 2 |
| Beta-lactam/Inhibitor | G5S | 2025-12 | 9 |
| Carbapenems | G5S | 2025-12 | 2 |
| Cephalosporins 1st Gen | G5S | 2025-12 | 12 |
| Cephalosporins 4th Gen | G5S | 2025-12 | 5 |
| Fluoroquinolones | G5S | 2025-12 | 5 |
| Glycopeptides | G5S | 2025-12 | 3 |
| Lincosamides | G5S | 2025-12 | 6 |
| Aminoglycosides | G5S | 2026-01 | 9 |
| Antifungals - Azoles | G5S | 2026-01 | 2 |
| Carbapenems | G5S | 2026-01 | 10 |
| Cephalosporins 4th Gen | G5S | 2026-01 | 5 |
| Fluoroquinolones | G5S | 2026-01 | 15 |
| Lincosamides | G5S | 2026-01 | 5 |
| Cephalosporins 1st Gen | G6N | 2025-12 | 2 |
| Glycopeptides | G6N | 2025-12 | 5 |
| Nitroimidazoles | G6N | 2025-12 | 4 |
| Antifungals - Azoles | G6N | 2026-01 | 5 |
| Beta-lactam/Inhibitor | G6N | 2026-01 | 11 |
| Cephalosporins 1st Gen | G6N | 2026-01 | 5 |
| Cephalosporins 3rd Gen | G6N | 2026-01 | 3 |
| Cephalosporins 4th Gen | G6N | 2026-01 | 11 |
| Fluoroquinolones | G6N | 2026-01 | 14 |
| Lincosamides | G6N | 2026-01 | 5 |
| Nitroimidazoles | G6N | 2026-01 | 7 |
| Antifungals - Azoles | T4 | 2025-12 | 4 |
| Antifungals - Azoles | T4 | 2026-01 | 8 |
| Cephalosporins 4th Gen | T4 | 2026-01 | 3 |
| Lincosamides | T4 | 2026-01 | 2 |
| Penicillins | T4 | 2026-01 | 3 |
| Aminoglycosides | T5A | 2025-12 | 11 |
| Cephalosporins 1st Gen | T5A | 2025-12 | 1 |
| Cephalosporins 3rd Gen | T5A | 2025-12 | 5 |
| Fluoroquinolones | T5A | 2025-12 | 3 |
| Glycopeptides | T5A | 2025-12 | 6 |
| Lincosamides | T5A | 2025-12 | 5 |
| Penicillins | T5A | 2025-12 | 3 |
| Aminoglycosides | T5A | 2026-01 | 5 |
| Antifungals - Azoles | T5A | 2026-01 | 8 |
| Beta-lactam/Inhibitor | T5A | 2026-01 | 20 |
| Penicillins | T5A | 2026-01 | 8 |
| Aminoglycosides | T5B | 2025-12 | 6 |
| Antifungals - Azoles | T5B | 2025-12 | 4 |
| Beta-lactam/Inhibitor | T5B | 2025-12 | 2 |
| Cephalosporins 1st Gen | T5B | 2025-12 | 5 |
| Cephalosporins 3rd Gen | T5B | 2025-12 | 3 |
| Glycopeptides | T5B | 2025-12 | 6 |
| Aminoglycosides | T5B | 2026-01 | 8 |
| Cephalosporins 3rd Gen | T5B | 2026-01 | 6 |
| Fluoroquinolones | T5B | 2026-01 | 3 |
| Glycopeptides | T5B | 2026-01 | 6 |
| Nitroimidazoles | T5B | 2026-01 | 3 |
| Penicillins | T5B | 2026-01 | 5 |
A6N - Summary
Total DOT: 19
Patient Days: 130
Rate: 146.15 DOT/1000 PD
2025-12 (22 patient days, 15 DOT, 681.82/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
CRO |
ceftriaxone | Cephalosporins 3rd Gen | IV | 3 | 136.36 | 3.0 |
FEP |
cefepime | Cephalosporins 4th Gen | IV | 5 | 227.27 | 8.0 |
VAN |
vancomycin | Glycopeptides | IV | 3 | 136.36 | 3.0 |
MTR |
metronidazole | Nitroimidazoles | IV | 4 | 181.82 | 1.33 |
2026-01 (42 patient days, 4 DOT, 95.24/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
FLU |
fluconazole | Antifungals - Azoles | IV | 4 | 95.24 | 18.0 |
G5S - Summary
Total DOT: 93
Patient Days: 1316
Rate: 70.67 DOT/1000 PD
2025-12 (77 patient days, 47 DOT, 610.39/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
GEN |
gentamicin | Aminoglycosides | IV | 3 | 38.96 | 4.0 |
FLU |
fluconazole | Antifungals - Azoles | IV | 2 | 25.97 | 6.0 |
TZP |
piperacillin/tazobactam | Beta-lactam/Inhibitor | IV | 9 | 116.88 | 4.5 |
MEM |
meropenem | Carbapenems | IV | 2 | 25.97 | 2.5 |
CFZ |
cefazolin | Cephalosporins 1st Gen | IV | 12 | 155.84 | 6.0 |
FEP |
cefepime | Cephalosporins 4th Gen | IV | 5 | 64.94 | 5.0 |
CIP |
ciprofloxacin | Fluoroquinolones | PO | 5 | 64.94 | 5.5 |
VAN |
vancomycin | Glycopeptides | IV | 3 | 38.96 | 1.5 |
CLI |
clindamycin | Lincosamides | IV | 6 | 77.92 | 5.0 |
2026-01 (89 patient days, 46 DOT, 516.85/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
AMK |
amikacin | Aminoglycosides | IV | 6 | 67.42 | 4.0 |
GEN |
gentamicin | Aminoglycosides | IV | 3 | 33.71 | 4.0 |
FLU |
fluconazole | Antifungals - Azoles | IV | 2 | 22.47 | 8.0 |
MEM |
meropenem | Carbapenems | IV | 10 | 112.36 | 10.5 |
FEP |
cefepime | Cephalosporins 4th Gen | IV | 5 | 56.18 | 15.0 |
CIP |
ciprofloxacin | Fluoroquinolones | PO | 15 | 168.54 | 18.0 |
CLI |
clindamycin | Lincosamides | IV | 5 | 56.18 | 5.5 |
G6N - Summary
Total DOT: 72
Patient Days: 913
Rate: 78.86 DOT/1000 PD
2025-12 (35 patient days, 11 DOT, 314.29/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
CFZ |
cefazolin | Cephalosporins 1st Gen | IV | 2 | 57.14 | 1.0 |
VAN |
vancomycin | Glycopeptides | IV | 5 | 142.86 | 3.5 |
MTR |
metronidazole | Nitroimidazoles | IV | 4 | 114.29 | 1.33 |
2026-01 (101 patient days, 61 DOT, 603.96/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
FLU |
fluconazole | Antifungals - Azoles | IV | 5 | 49.5 | 30.0 |
TZP |
piperacillin/tazobactam | Beta-lactam/Inhibitor | IV | 11 | 108.91 | 8.36 |
CFZ |
cefazolin | Cephalosporins 1st Gen | IV | 5 | 49.5 | 2.67 |
CRO |
ceftriaxone | Cephalosporins 3rd Gen | IV | 3 | 29.7 | 6.0 |
FEP |
cefepime | Cephalosporins 4th Gen | IV | 11 | 108.91 | 22.0 |
CIP |
ciprofloxacin | Fluoroquinolones | PO | 14 | 138.61 | 13.0 |
CLI |
clindamycin | Lincosamides | IV | 5 | 49.5 | 7.0 |
MTR |
metronidazole | Nitroimidazoles | IV | 7 | 69.31 | 3.67 |
T4 - Summary
Total DOT: 20
Patient Days: 214
Rate: 93.46 DOT/1000 PD
2025-12 (50 patient days, 4 DOT, 80.0/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
FLU |
fluconazole | Antifungals - Azoles | IV | 4 | 80.0 | 20.0 |
2026-01 (41 patient days, 16 DOT, 390.24/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
FLU |
fluconazole | Antifungals - Azoles | IV | 8 | 195.12 | 26.0 |
FEP |
cefepime | Cephalosporins 4th Gen | IV | 3 | 73.17 | 7.0 |
CLI |
clindamycin | Lincosamides | IV | 2 | 48.78 | 1.0 |
AMP |
ampicillin | Penicillins | IV | 3 | 73.17 | 3.0 |
T5A - Summary
Total DOT: 75
Patient Days: 1170
Rate: 64.1 DOT/1000 PD
2025-12 (65 patient days, 34 DOT, 523.08/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
AMK |
amikacin | Aminoglycosides | IV | 6 | 92.31 | 3.0 |
GEN |
gentamicin | Aminoglycosides | IV | 5 | 76.92 | 8.0 |
CFZ |
cefazolin | Cephalosporins 1st Gen | IV | 1 | 15.38 | 0.33 |
CRO |
ceftriaxone | Cephalosporins 3rd Gen | IV | 5 | 76.92 | 8.0 |
CIP |
ciprofloxacin | Fluoroquinolones | PO | 3 | 46.15 | 3.5 |
VAN |
vancomycin | Glycopeptides | IV | 6 | 92.31 | 3.0 |
CLI |
clindamycin | Lincosamides | IV | 5 | 76.92 | 5.0 |
AMP |
ampicillin | Penicillins | IV | 3 | 46.15 | 7.0 |
2026-01 (130 patient days, 41 DOT, 315.38/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
AMK |
amikacin | Aminoglycosides | IV | 1 | 7.69 | 0.5 |
GEN |
gentamicin | Aminoglycosides | IV | 4 | 30.77 | 5.0 |
FLU |
fluconazole | Antifungals - Azoles | IV | 8 | 61.54 | 42.0 |
TZP |
piperacillin/tazobactam | Beta-lactam/Inhibitor | IV | 20 | 153.85 | 13.5 |
AMP |
ampicillin | Penicillins | IV | 8 | 61.54 | 20.0 |
T5B - Summary
Total DOT: 57
Patient Days: 707
Rate: 80.62 DOT/1000 PD
2025-12 (38 patient days, 26 DOT, 684.21/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
AMK |
amikacin | Aminoglycosides | IV | 3 | 78.95 | 3.5 |
GEN |
gentamicin | Aminoglycosides | IV | 3 | 78.95 | 3.0 |
FLU |
fluconazole | Antifungals - Azoles | IV | 4 | 105.26 | 8.0 |
TZP |
piperacillin/tazobactam | Beta-lactam/Inhibitor | IV | 2 | 52.63 | 0.64 |
CFZ |
cefazolin | Cephalosporins 1st Gen | IV | 5 | 131.58 | 5.0 |
CRO |
ceftriaxone | Cephalosporins 3rd Gen | IV | 3 | 78.95 | 5.0 |
VAN |
vancomycin | Glycopeptides | IV | 6 | 157.89 | 3.0 |
2026-01 (63 patient days, 31 DOT, 492.06/1000 PD)
| NHSN Code | Medication | Category | Route | DOT | DOT/1000 PD | DDD |
|---|---|---|---|---|---|---|
AMK |
amikacin | Aminoglycosides | IV | 4 | 63.49 | 2.5 |
GEN |
gentamicin | Aminoglycosides | IV | 4 | 63.49 | 5.0 |
CRO |
ceftriaxone | Cephalosporins 3rd Gen | IV | 6 | 95.24 | 14.0 |
CIP |
ciprofloxacin | Fluoroquinolones | PO | 3 | 47.62 | 1.5 |
VAN |
vancomycin | Glycopeptides | IV | 6 | 95.24 | 7.0 |
MTR |
metronidazole | Nitroimidazoles | IV | 3 | 47.62 | 1.67 |
AMP |
ampicillin | Penicillins | IV | 5 | 79.37 | 15.0 |